Gene-guided Warfarin for Anticoagulation Therapy (GWAT)

Xi'an Jiaotong University

Status: Withdrawn

Conditions: Stroke

Treatments: Drug: Warfarin Sodium; Device: Gene detection (CYP2C9*3, VKORC1)

Study type: Interventional

Funder types: Other

Identifiers

NCT04482842

XJTU1AF2020LSK-067

Details and patient eligibility

About

This study will explore the effect of warfarin gene polymorphism on the effectiveness and safety of anticoagulant therapy in patients with acute ischemic stroke, and clarify the correlation between genetic testing and compliance rate of INR value. It will illustrate the significance of gene-guided warfarin for administered dose to anticoagulation therapy in patients with acute ischemic stroke. Then it will establish and verify a warfarin stable dose prediction model suitable for such patients, and provide basis for the personalized medication regimen of warfarin in patients with acute ischemic stroke.

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with acute ischemic stroke aged ≥18 years (cardiogenic cerebral embolism patients)
• Clinicians judge that long-term oral anticoagulation with warfarin is required
• No anticoagulation treatment in the past 10 days
• Agree to participate in this project

Exclusion criteria

• Patients who had a tendency to bleed when taking warfarin
• High-risk groups using warfarin anticoagulation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups

Gene-guided Warfarin

Experimental group

Treatment:

Drug: Warfarin Sodium

Device: Gene detection (CYP2C9*3, VKORC1)

Routine use

Other group

Treatment:

Drug: Warfarin Sodium